SG10201405403QA - Novel salts of dpp-iv inhibitor - Google Patents

Novel salts of dpp-iv inhibitor

Info

Publication number
SG10201405403QA
SG10201405403QA SG10201405403QA SG10201405403QA SG10201405403QA SG 10201405403Q A SG10201405403Q A SG 10201405403QA SG 10201405403Q A SG10201405403Q A SG 10201405403QA SG 10201405403Q A SG10201405403Q A SG 10201405403QA SG 10201405403Q A SG10201405403Q A SG 10201405403QA
Authority
SG
Singapore
Prior art keywords
dpp
inhibitor
novel salts
salts
novel
Prior art date
Application number
SG10201405403QA
Inventor
Bipin Pandey
Mayank Ghanshyambhai Dave
Himanshu M Kothari
Bhavin Shriprasad Shukla
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of SG10201405403QA publication Critical patent/SG10201405403QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201405403QA 2011-03-03 2012-03-02 Novel salts of dpp-iv inhibitor SG10201405403QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN590MU2011 2011-03-03
IN1948MU2011 2011-07-06
IN2777MU2011 2011-09-30

Publications (1)

Publication Number Publication Date
SG10201405403QA true SG10201405403QA (en) 2014-11-27

Family

ID=54290089

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013064886A SG192973A1 (en) 2011-03-03 2012-03-02 Novel salts of dpp-iv inhibitor
SG10201405403QA SG10201405403QA (en) 2011-03-03 2012-03-02 Novel salts of dpp-iv inhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013064886A SG192973A1 (en) 2011-03-03 2012-03-02 Novel salts of dpp-iv inhibitor

Country Status (13)

Country Link
US (1) US9108972B2 (en)
EP (4) EP2681220B1 (en)
JP (1) JP2014510071A (en)
KR (1) KR20130132631A (en)
CN (2) CN104788456A (en)
AU (1) AU2012247127B2 (en)
BR (1) BR112013022504A8 (en)
DK (1) DK2681220T3 (en)
ES (1) ES2548269T3 (en)
MX (1) MX2013010027A (en)
PH (1) PH12015501536A1 (en)
SG (2) SG192973A1 (en)
WO (1) WO2012147092A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2788352A1 (en) * 2011-12-08 2014-10-15 Ranbaxy Laboratories Limited Amorphous form of sitagliptin salts
MX2016016260A (en) 2016-12-08 2018-06-07 Alparis Sa De Cv New solid forms of sitagliptin.
GR1010089B (en) 2020-09-15 2021-09-27 Φαρματεν Α.Β.Ε.Ε. Solid dosage form comprising sitagliptin and method of preparation thereof
GR1010234B (en) 2021-04-27 2022-05-18 Φαρματεν Α.Β.Ε.Ε., Pharmaceutical composition comprising a combination of sitagliptin and metformin and method of preparation thereof
WO2023139276A1 (en) 2022-01-24 2023-07-27 Zaklady Farmaceutyczne Polpharma S.A. Process for preparing crystalline sitagliptin hydrochloride monohydrate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
AU2004268024B2 (en) 2003-09-02 2007-07-12 Merck Sharp & Dohme Llc Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
EP1667524A4 (en) 2003-09-23 2009-01-14 Merck & Co Inc Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US20080227786A1 (en) * 2004-01-16 2008-09-18 Ferlita Russell R Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
WO2006033848A1 (en) 2004-09-15 2006-03-30 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2006127530A2 (en) * 2005-05-25 2006-11-30 Merck & Co., Inc. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1909776A2 (en) 2005-07-25 2008-04-16 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
JP2009513633A (en) * 2005-10-25 2009-04-02 メルク エンド カムパニー インコーポレーテッド Combination of dipeptidyl peptidase-4 inhibitor and antihypertensive agent for the treatment of diabetes and hypertension
AU2007264030B2 (en) 2006-06-27 2012-04-05 Sandoz Ag New method for salt preparation
CA2666136A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
ATE545416T1 (en) * 2006-10-12 2012-03-15 Xenon Pharmaceuticals Inc USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTICS
EP2019113A1 (en) * 2007-07-26 2009-01-28 Anadys Pharmaceuticals, Inc. New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one
EA020658B1 (en) * 2007-08-09 2014-12-30 Ренссилэйер Политекник Инститьют Quaternary opioid carboxamides
US8309724B2 (en) * 2007-12-20 2012-11-13 Dr. Reddy's Laboratories Limited Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
EP2318411A2 (en) 2008-07-03 2011-05-11 Ratiopharm GmbH Crystalline salts of sitagliptin
FR2933692B1 (en) * 2008-07-10 2022-12-02 Univ Nancy 1 Henri Poincare NEW COMPOUNDS, THEIR USE AS MEDICINES, AND METHOD FOR PREPARING THEM
US20100069637A1 (en) * 2008-07-29 2010-03-18 Medichem S.A. CRYSTALLINE SALT FORMS OF A 5,6,7,8-TETRAHYDRO-1,2,4-TRIAZOLO[4,3-a]PYRAZINE DERIVATIVE
WO2010032264A2 (en) 2008-08-27 2010-03-25 Cadila Healthcare Limited Improved process for preparation of (2r)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin- 7(8h)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine & new impurities in preparation thereof
ES2603215T3 (en) * 2008-12-31 2017-02-24 Chiral Quest, Inc. Process and intermediate products for the preparation of N-acylated-4-aryl beta-amino acid derivatives
EP2218721A1 (en) 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
EP2398803A2 (en) 2009-03-30 2011-12-28 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts
EP2407469A1 (en) 2010-07-13 2012-01-18 Chemo Ibérica, S.A. Salt of sitagliptin
CA2840806A1 (en) * 2011-06-30 2013-01-03 Ranbaxy Laboratories Limited Novel salts of sitagliptin

Also Published As

Publication number Publication date
US9108972B2 (en) 2015-08-18
US20140051856A1 (en) 2014-02-20
WO2012147092A2 (en) 2012-11-01
BR112013022504A2 (en) 2016-07-19
CN104788456A (en) 2015-07-22
DK2681220T3 (en) 2015-11-30
SG192973A1 (en) 2013-09-30
BR112013022504A8 (en) 2018-01-23
AU2012247127B2 (en) 2016-01-28
ES2548269T3 (en) 2015-10-15
CN103476778A (en) 2013-12-25
EP2681220A2 (en) 2014-01-08
EP2789616A1 (en) 2014-10-15
WO2012147092A3 (en) 2013-03-14
JP2014510071A (en) 2014-04-24
EP2899194A1 (en) 2015-07-29
AU2012247127A1 (en) 2013-10-03
EP2860180A1 (en) 2015-04-15
KR20130132631A (en) 2013-12-04
MX2013010027A (en) 2014-02-11
EP2681220B1 (en) 2015-08-19
PH12015501536A1 (en) 2015-09-21

Similar Documents

Publication Publication Date Title
HK1257823A1 (en) Metalloenzyme inhibitor compounds
HK1198163A1 (en) Metalloenzyme inhibitor compounds
HK1198651A1 (en) Metalloenzyme inhibitor compounds
HRP20180139T1 (en) Substituted pyridopyrazines as novel syk inhibitors
ZA201309561B (en) Novel inhibitor compounds of phosphodiestarase type 10a
HK1201519A1 (en) Inhibitors of phosphodiesterase type 10a 10a
EP2723731A4 (en) Metalloenzyme inhibitor compounds
ZA201306580B (en) Cyclopropylamines as lsd1 inhibitors
EP2683693A4 (en) Rorgammat inhibitors
EP2726075A4 (en) Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
HK1195770A1 (en) Amorphous solid salts of cobicistat (gs-9350) (cobicistat)(gs-9350)
EP2760853A4 (en) Novel salts of alogliptin
EP2744788A4 (en) Benzopiperazine derivatives as cetp inhibitors
SG10201405403QA (en) Novel salts of dpp-iv inhibitor
EP2759296A4 (en) Gip elevation inhibitor
EP2751117A4 (en) Metalloenzyme inhibitor compounds
AP2013007101A0 (en) Novel salts of DPP-IV inhibitor
GB201104399D0 (en) Novel inhibitors
GB201120474D0 (en) Inhibitors
GB201106819D0 (en) Novel salts
GB201108188D0 (en) Corrosion inhibitor